Physician profile
Matthew Boyer
NPI 1346245453
$5,611.70
in general payments reported to CMS, 2019-2025
25 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,085 · 2020: $634 · 2021: $566 · 2022: $830 · 2023: $945 · 2024: $1,000 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,373 · Education: $97.99 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.26 |
| Education | $97.99 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $889.74 | 2022-2025 | Envista Mx60 Iol, Miebo, Vyzulta |
| Abbvie INC. | $780.30 | 2022-2025 | Lumigan, Durysta, Alphagan P |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $702.86 | 2019-2021 | |
| Allergan, INC. | $475.76 | 2019-2022 | |
| Rxsight INC | $451.52 | 2021-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Alcon Vision LLC | $359.36 | 2019-2025 | Tryptyr, Rocklatan |
| Aerie Pharmaceuticals, INC. | $333.61 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $277.78 | 2023-2025 | Acthar |
| Glaukos Corporation | $184.75 | 2020-2025 | Istent Infinite, Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Sun Pharmaceutical Industries INC. | $172.64 | 2019-2025 | Cequa |
| Regeneron Healthcare Solutions, INC. | $150.11 | 2019-2023 | Eylea Hd |
| Novartis Pharmaceuticals Corporation | $135.60 | 2021-2023 | |
| Omeros Corporation | $131.55 | 2019-2020 | |
| Dompe US, INC. | $130.83 | 2021-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $96.18 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $67.36 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $64.45 | 2019-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $48.12 | 2020-2021 | |
| Rayner Intraocular Lenses Limited | $33.10 | 2022 | |
| Oyster Point Pharma, INC. | $30.28 | 2023 | Tyrvaya |
| Amgen INC. | $21.97 | 2025 | Tepezza |
| Harrow Eye, LLC | $20.51 | 2025 | Vevye |
| Ocular Therapeutix, INC. | $18.76 | 2020 | |
| New World Medical,INC. | $18.36 | 2021 | |
| Sight Sciences, INC. | $16.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Boyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.